Clinical Trial Update: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update notes the completion of the first-in-human Phase 1/2 study of REGN5459 in adults with relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• REGN5459 (REGN5459)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED